Prognostic significance of an early decline in serum alpha-fetoprotein during chemotherapy for ovarian yolk sac tumors.

MLA

de la Motte Rouge, Thibault, et al. “Prognostic Significance of an Early Decline in Serum Alpha-Fetoprotein during Chemotherapy for Ovarian Yolk Sac Tumors.” Gynecologic Oncology, vol. 142, no. 3, Sept. 2016, pp. 452–57. EBSCOhost, https://doi.org/10.1016/j.ygyno.2016.07.005.

APA

de la Motte Rouge, T., Pautier, P., Genestie, C., Rey, A., Gouy, S., Leary, A., Haie-Meder, C., Kerbrat, P., Culine, S., Fizazi, K., & Lhommé, C. (2016). Prognostic significance of an early decline in serum alpha-fetoprotein during chemotherapy for ovarian yolk sac tumors. Gynecologic Oncology, 142(3), 452–457. https://doi.org/10.1016/j.ygyno.2016.07.005

Chicago

de la Motte Rouge, Thibault, Patricia Pautier, Catherine Genestie, Annie Rey, Sébastien Gouy, Alexandra Leary, Christine Haie-Meder, et al. 2016. “Prognostic Significance of an Early Decline in Serum Alpha-Fetoprotein during Chemotherapy for Ovarian Yolk Sac Tumors.” Gynecologic Oncology 142 (3): 452–57. doi:10.1016/j.ygyno.2016.07.005.